文献速递儿童呼吸

静脉硫酸镁辅助治疗儿童急性哮喘发作的系统综述与荟萃分析

Use of intravenous magnesium sulfate in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2 agonist and systemic steroids in the management of acute asthma exacerbations in children: a systematic review and meta-analyses of randomised controlled trials.
PubMed 文献 · Arch Dis Child · 2025-11-19

该系统综述与荟萃分析共纳入9项随机对照试验(473例患儿),评估在标准一线治疗(吸入短效β2受体激动剂和全身激素)基础上加用静脉硫酸镁的疗效与安全性。结果显示静脉硫酸镁组住院率较低(MD=0.70,95%CI 0.54-0.90)且无创通气需求较少(RR=0.17,95%CI 0.15-0.54,p=0.003),但哮喘严重度评分、住院时长、有创通气需求和PICU入住率无显著差异,无严重不良事件报告。证据确定性低,但安全性良好,可考虑作为哮喘急性发作的治疗选择。

要点

  • 静脉硫酸镁可降低住院率(MD=0.70,95%CI 0.54-0.90)和无创通气需求(RR=0.17,95%CI 0.15-0.54)。
  • 哮喘严重度评分、住院时长、有创通气及PICU入住率与对照组无显著差异。
  • 无严重不良事件报告,但证据确定性低。

核心结论

  • 静脉硫酸镁辅助标准一线治疗可降低住院率和无创通气需求,但哮喘评分、PICU入住、有创通气和住院时长无差异,证据确定性低且安全性良好。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE、CINAHL、Cochrane Central Register of Controlled Trials和Web of Science至2024年5月,纳入9项随机对照试验共473例患儿。

主要发现

  • 住院率在静脉硫酸镁组较低(MD=0.70,95%CI 0.54至0.90,I2=7%,n=115)。
  • 无创通气需求在静脉硫酸镁组较少(RR=0.17,95%CI 0.15至0.54,p=0.003,n=143)。
  • 哮喘严重度评分(MD=-0.18,95%CI -1.35至0.98,I2=2%,n=115)、住院时长(MD=-78.86,95%CI -200.37至42.66,I2=99%,n=284)和有创通气需求(RR=0.35,95%CI 0.11至1.17,I2=0%,n=237)组间相似。
  • PICU入住率无差异(p=0.43,n=61),静脉硫酸镁组呼气峰流量改善(p<0.001,n=20)。
  • 无严重不良事件报告。

关键数值与推荐

  • 住院率MD=0.70(95%CI 0.54至0.90,I2=7%,n=115)。
  • 无创通气需求RR=0.17(95%CI 0.15至0.54,p=0.003,n=143)。
  • 哮喘严重度评分MD=-0.18(95%CI -1.35至0.98,I2=2%,n=115)。
  • 住院时长MD=-78.86(95%CI -200.37至42.66,I2=99%,n=284)。
  • 有创通气需求RR=0.35(95%CI 0.11至1.17,I2=0%,n=237)。

临床怎么用

  • 在标准一线治疗(吸入短效β2受体激动剂和全身激素)基础上,可考虑加用静脉硫酸镁以降低住院率和无创通气需求。
  • 需注意证据确定性低,临床决策应结合患儿具体情况。

局限性

  • 证据确定性低,证据基础薄弱。
  • 部分结局指标样本量小(如呼气峰流量n=20,PICU入住n=61)。
  • 住院时长分析异质性高(I2=99%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of intravenous magnesium sulfate in asthma exacerbation is unclear. AIMS: To determine the efficacy and safety of intravenous magnesium sulfate in managing asthma exacerbation in children. METHODS: We searched MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials and the Web of Science up to May 2024. We included randomised controlled trials and followed the international guidelines for conducting systematic reviews. Outcomes included morbidity, escalation of care, length of hospital stay, lung functions, adverse events, and mortality. RESULTS: Nine studies (total participants=473) were included. Hospitalisation rate and the need for non-invasive ventilation were less among the intravenous magnesium sulfate group (mean difference (MD)=0.70, 95% CI 0.54 to 0.90, I2 7%, n=115) and (risk ratio (RR)=0.17, 95% CI 0.15 to 0.54, p=0.003, n=143), respectively. Asthma severity scores (MD=-0.18, 95% CI -1.35 to 0.98, I2 2%, n=115), length of hospital stay (MD=-78.86, 95% CI -200.37 to 42.66, I2 99%, n=284) and the need for invasive ventilation (RR=0.35, 95% CI 0.11 to 1.17, I2 0%, n=237) were similar. There was no difference in the Paediatric Intensive Care Unit (PICU) admission rate (p=0.43 n=61). Peak expiratory flow improved in the intravenous magnesium group (p<0.001, n=20). No serious adverse events were reported. CONCLUSION: We found low-certainty evidence that intravenous magnesium sulfate results in a lower hospitalisation rate and less need for non-invasive ventilation. Asthma scores, PICU admission, invasive ventilation and length of hospital stay were similar. While the evidence base is weak, the favourable safety profile suggests that intravenous magnesium sulfate can be considered a treatment for asthma exacerbations. PROSPERO REGISTRATION NUMBER: CRD42023405261.

来源:Arch Dis Child,查看原文。版权归原作者所有。

引用

  1. Hamud AA, Mudawi K, Powell C, et al. Use of intravenous magnesium sulfate in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2 agonist and systemic steroids in the management of acute asthma exacerbations in children: a systematic review and meta-analyses of randomised controlled trials. Arch Dis Child. 2025. PMID: 40562459. doi:10.1136/archdischild-2024-327486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。